全文获取类型
| 收费全文 | 16554篇 |
| 免费 | 848篇 |
| 国内免费 | 125篇 |
专业分类
| 耳鼻咽喉 | 151篇 |
| 儿科学 | 335篇 |
| 妇产科学 | 367篇 |
| 基础医学 | 1900篇 |
| 口腔科学 | 404篇 |
| 临床医学 | 1236篇 |
| 内科学 | 5169篇 |
| 皮肤病学 | 414篇 |
| 神经病学 | 1297篇 |
| 特种医学 | 301篇 |
| 外科学 | 2376篇 |
| 综合类 | 97篇 |
| 一般理论 | 8篇 |
| 预防医学 | 1058篇 |
| 眼科学 | 301篇 |
| 药学 | 921篇 |
| 中国医学 | 37篇 |
| 肿瘤学 | 1155篇 |
出版年
| 2024年 | 13篇 |
| 2023年 | 138篇 |
| 2022年 | 310篇 |
| 2021年 | 701篇 |
| 2020年 | 315篇 |
| 2019年 | 625篇 |
| 2018年 | 693篇 |
| 2017年 | 411篇 |
| 2016年 | 421篇 |
| 2015年 | 451篇 |
| 2014年 | 743篇 |
| 2013年 | 827篇 |
| 2012年 | 1492篇 |
| 2011年 | 1517篇 |
| 2010年 | 781篇 |
| 2009年 | 704篇 |
| 2008年 | 1124篇 |
| 2007年 | 1120篇 |
| 2006年 | 975篇 |
| 2005年 | 935篇 |
| 2004年 | 859篇 |
| 2003年 | 685篇 |
| 2002年 | 698篇 |
| 2001年 | 78篇 |
| 2000年 | 73篇 |
| 1999年 | 96篇 |
| 1998年 | 107篇 |
| 1997年 | 103篇 |
| 1996年 | 73篇 |
| 1995年 | 47篇 |
| 1994年 | 54篇 |
| 1993年 | 39篇 |
| 1992年 | 35篇 |
| 1991年 | 27篇 |
| 1990年 | 26篇 |
| 1989年 | 19篇 |
| 1988年 | 19篇 |
| 1987年 | 17篇 |
| 1986年 | 13篇 |
| 1985年 | 11篇 |
| 1984年 | 19篇 |
| 1983年 | 13篇 |
| 1982年 | 12篇 |
| 1981年 | 12篇 |
| 1980年 | 12篇 |
| 1979年 | 11篇 |
| 1978年 | 7篇 |
| 1975年 | 11篇 |
| 1971年 | 11篇 |
| 1970年 | 5篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
1.
2.
3.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
4.
5.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献6.
Miguel A. Sanz Pau Montesinos Haesook T. Kim Guillermo J. Ruiz-Argüelles María S. Undurraga María R. Uriarte Lem Martínez Rafael H. Jacomo Homero Gutiérrez-Aguirre Raul A. M. Melo Rosane Bittencourt Ricardo Pasquini Katia Pagnano Evandro M. Fagundes Edo Vellenga Alexandra Holowiecka Ana J. González-Huerta Pascual Fernández Javier De la Serna Salut Brunet Elena De Lisa José González-Campos José M. Ribera Isabel Krsnik Arnold Ganser Nancy Berliner Raul C. Ribeiro Francesco Lo-Coco Bob L?wenberg Eduardo M. Rego 《Annals of hematology》2015,94(8):1347-1356
7.
Maite Cruz Piqueras Ainhoa Rodríguez García de Cortazar Joaquín Hortal Carmona Javier Padilla Bernáldez 《Gaceta sanitaria / S.E.S.P.A.S》2019,33(1)
Objective
To analyse and understand vaccination hesitancy discourses, particularly those of people who have decided not to vaccinate their sons and daughters.Methods
Qualitative study of five individual interviews and two focus groups with people who chose not to vaccinate their children in the province of Granada (Spain).Results
Mothers and fathers manifest a system of health beliefs different to the biomedical paradigm. From an ethical point of view, they justify their position based on the right to autonomy and responsibility for their decisions. Alleged specific reasons: they doubt administration of several vaccines simultaneously at an early age in a systematic way and without individualising each case; they fear adverse effects and do not understand the variations of the vaccination schedule.Conclusions
These vaccination hesitancy discourses respond to the individual vs collective conflict; parents defend their right to bring up their children without any interference from the state and focus their responsibility on the individual welfare of their sons and daughters, regardless of the consequences that their actions might have on the collective. In their management of risks, they consider those derived from vaccination more relevant than the individual or collective consequences of not doing so. The vaccines generating most doubts are the more controversial ones within the scientific world. Transparency in communication of adverse effects; authorities respect for other health/disease concepts; banishment of the term “anti-vaccines” from the media and scientific vocabulary, and developing spaces for dialogue are bridges to be built. 相似文献8.
Modena Débora Aparecida Oliveira Miranda Ana Carolina Godoy Grecco Clovis Liebano Richard Eloin Cordeiro Raquel Cristina Tancsik Guidi Renata Michelini 《Lasers in medical science》2020,35(4):797-806
Lasers in Medical Science - Using light sources in phototherapy has presented promising results regarding several types of facial and body skin affections for centuries. The neodymium-doped yttrium... 相似文献
9.
10.